These data indicated that the growth inhibitory effects of fimepinostat in prostate cancer are broad and extend beyond the observed effects of fimepinostat on AR and Myc expression which was consistent with our initial observation of the broad activity of fimepinostat across prostate cancer cell lines including AR-null and NE phenotypes. This evidence concerns the gene MYC and prostate cancer.